Ipca Laboratories: Business Overview & Financial Analysis
Ipca Laboratories Limited is a pharmaceutical company headquartered in Mumbai, Maharashtra. Promoted by the Godha and Chordia families, the company manufactures and markets Active Pharmaceutical Ingredients (APIs) and finished dosage formulations across more than 100 countries. Operating an integrated network of 18 manufacturing facilities in India, Ipca Laboratories maintains therapeutic market leadership in pain management, rheumatology, antimalarials, cardiovascular care, and central nervous system (CNS) treatments.
Business Segment Breakdown of Ipca Laboratories (FY26)
Ipca Laboratories generates its operating revenue through finished formulations and Active Pharmaceutical Ingredients (APIs).
- Domestic Formulations – Rs 3,817.24 crore (39.6%)
- Export Formulations – Rs 3,129.43 crore (32.4%)
- Active Pharmaceutical Ingredients (APIs) – Rs 1,380.50 crore (14.3%)
- Subsidiaries & Unichem Business – Rs 1,319.16 crore (13.7%)
- Total Consolidated Revenue – Rs 9,646.33 crore (100.0%)
Domestic formulations form the largest revenue contributor, outperforming broader Indian Pharmaceutical Market (IPM) growth rates. The formulation and API divisions maintain backward integration capabilities, producing over 350 formulations and 80 APIs in-house.
Geographic & Sales Revenue Mix of Ipca Laboratories (FY26)
Ipca Laboratories distributes products across domestic healthcare channels and international regulated and emerging markets.
- Indian Domestic Market Share – 53.3% of Total Revenue
- International Formulations & APIs Exports – 46.7% of Total Revenue
- US Consolidated Market Turnover – Rs 1,567.00 crore
- European & UK Formulations Share – ~12.0% of Export Sales
- Rest of the World (RoW) & Institutional Sales Share – ~18.0% of Export Sales
The Indian domestic market provides stable cash flows, supported by a salesforce covering metro, urban, and semi-urban medical centers. International sales span over 100 countries, with the United States driving export volume growth following the consolidation of Unichem Laboratories.
Therapeutic Portfolio & Brand Performance of Ipca Laboratories (FY26)
Ipca Laboratories ranks 16th in the Indian Pharmaceutical Market (IPM), holding a market share of approximately 2.10%.
- Pain Management & Rheumatology Share – ~42% of Domestic Formulations
- Cardiovascular & Anti-Hypertensives Share – ~20% of Domestic Formulations
- Anti-Infectives & Antimalarials Share – ~14% of Domestic Formulations
- Central Nervous System (CNS) & Dermatology Share – ~12% of Domestic Formulations
- Top 10 Domestic Brands Sales Contribution – 39.0%
- Number of Top 300 IPM Ranking Brands – 6 Brands
The company maintains leading market positions in molecules such as Hydroxychloroquine Sulphate, Metoprolol Succinate, Chloroquine Phosphate, and Zerodol. Acute and chronic portfolios both outpaced industry averages, driven by brand building in metro markets.
Manufacturing Network & USFDA Regulatory Compliance of Ipca Laboratories (FY26)
Ipca Laboratories operates an integrated manufacturing footprint comprising API synthesis units and formulation plants.
- Total Operational Manufacturing Facilities – 26 facilities globally (15 API & 11 Formulations)
- Primary API Manufacturing Hub – Ratlam (Madhya Pradesh)
- Establishment Inspection Report (EIR) Status (Tarapur API) – VAI (Voluntary Action Indicated)
- Piparia Formulations Facility Classification – VAI (Voluntary Action Indicated)
- Ratlam API Expansion Project Outlay – Capacity doubling from 1,202 MT to 2,551.5 MT
Manufacturing operations are supported by two dedicated R&D centers in Mumbai and Vadodara handling process chemistry and formulation development. Recent USFDA inspections at key plants like Tarapur and Piparia resulted in Voluntary Action Indicated (VAI) classifications, facilitating product approvals.
Subsidiaries & Unichem Laboratories Integration of Ipca Laboratories (FY26)
Ipca Laboratories manages strategic international subsidiaries alongside its controlling stake in Unichem Laboratories Limited.
- Controlling Stake in Unichem Laboratories – ~56.0% equity holding
- Unichem Annual Revenue Contribution – ~Rs 2,200 crore
- Combined US ANDA Portfolio – 75+ filings and 60+ approvals
- Expected Unichem EBITDA Margin Improvement – 12.0%–13.0% (target for FY27)
Unichem Laboratories provides complimentary formulation capacity and direct ANDA distribution infrastructure in the United States. Synergies include rationalising overseas facilities and reducing European administrative overheads to lift operating margins.
Latest Quarterly Performance of Ipca Laboratories (Q4 FY26)
Ipca Laboratories recorded top-line growth and operating profit expansion during the fourth quarter of FY26.
- Consolidated Revenue from Operations – Rs 2,388.48 crore (+6.3% YoY)
- Domestic Formulations Revenue – Rs 853.00 crore (+12.0% YoY)
- Consolidated Operating EBITDA – Rs 483.90 crore (+13.0% YoY)
- Operating EBITDA Margin – 20.26% (+120 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 299.07 crore (+35.0% YoY)
- Board Recommended Final Dividend – Rs 6.00 per share (600%)
Fourth-quarter top-line revenue reached Rs 2,388.48 crore, propelled by a 12.0% surge in domestic formulation dispatches. Consolidated net profit rose 35.0% to Rs 299.07 crore, supported by lower raw material costs and product mix optimisation.
Consolidated Annual Financial Performance of Ipca Laboratories (FY26)
Ipca Laboratories delivered operating profit expansion and margin recovery during the full financial year FY26.
- Consolidated Revenue from Operations – Rs 9,646.33 crore (+7.9% YoY)
- Standalone Revenue from Operations – Rs 7,336.75 crore (+10.2% YoY)
- Consolidated Operating EBITDA – Rs 1,998.70 crore (+18.1% YoY)
- Consolidated EBITDA Margin – 20.72% (+178 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 1,141.12 crore (+54.7% YoY)
- Standalone Net Profit After Tax (PAT) – Rs 1,132.52 crore (+73.8% YoY)
Full-year consolidated revenue touched Rs 9,646.33 crore, driven by formulation growth in India and export markets. Consolidated net profit expanded 54.7% to Rs 1,141.12 crore, as EBITDA margins improved by 178 basis points to 20.72%.
Management Commentary & Strategic Guidance of Ipca Laboratories Limited (FY27)
Management guidance outlines revenue targets, margin improvement objectives, and capital allocation plans for FY27.
- Management projects consolidated revenue growth of 12.0%–13.0% in INR terms for FY27.
- Consolidated EBITDA margins are guided to reach 22.0%–22.3% during FY27.
- Domestic branded formulation business is targeted to grow ~12.0%, supported by 6.0%–7.0% price increases and new product launches.
- Unichem US operations are guided to achieve ~10.0% top-line growth with operating margins recovering to 12.0%–13.0%.
- US commercialisations are projected at 6 to 8 new generic formulation launches during FY27.
Management expects input cost inflation in raw materials like paracetamol and solvent freights to be fully absorbed by domestic price adjustments. Capital deployment will focus on completing the Ratlam API capacity expansion and integrating Unichem's US supply chain.
Sources & References
- Ipca Laboratories Limited Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
- Ipca Laboratories Limited Investor Presentation & Earnings Call Summary (May 2026)
- BSE India & NSE Corporate Disclosures for Ipca Laboratories Limited
- Ticker Finology Ipca Laboratories Page
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters
Disclaimer
The information presented above on Ipca Laboratories Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Ipca Laboratories Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.